Abstract
These 4 hypothetical cases highlight some of the new features in the 2018 American Heart Association/American College of Cardiology multisociety cholesterol management guidelines. Topics include management issues in a secondary prevention patient judged to be at very high risk of another event, a patient with familial hypercholesterolemia with a low-density lipoprotein cholesterol level of 190 mg/dL or greater (to convert to millimoles per liter, multiply by 0.0259), a primary prevention patient with intermediate (7.5%-19.9%) 10-year atherosclerotic cardiovascular risk, and a patient who has statin-associated adverse effects. A multiple-choice format is used to engage clinicians in selecting the best choice based on guidance from the new 2018 cholesterol management guidelines.
MeSH terms
-
Adult
-
American Heart Association / organization & administration
-
Anticholesteremic Agents / therapeutic use
-
Atherosclerosis / complications
-
Atherosclerosis / prevention & control*
-
Cardiology / organization & administration
-
Cardiovascular Diseases / prevention & control
-
Cholesterol, LDL / blood
-
Cholesterol, LDL / drug effects*
-
Ezetimibe / therapeutic use
-
Female
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hypercholesterolemia / drug therapy*
-
Male
-
Middle Aged
-
Practice Guidelines as Topic / standards*
-
Primary Prevention / standards
-
Secondary Prevention / standards
-
United States / epidemiology
Substances
-
Anticholesteremic Agents
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Ezetimibe